Literature DB >> 31510844

Ponatinib use in two pediatric patients with relapsed Ph + ALL with ABL1 kinase domain mutations.

Stephanie E Gruner1, Hadi Sayeed2, Lizmery Suarez-Ferguson2, Cintia Perez2, Rayne Rouce1,3, Kevin E Fisher1,2, Rachel E Rau1.   

Abstract

Entities:  

Keywords:  BCR/ABL1 kinase point mutation analysis; Ponatinib; T315I mutation; pediatric; relapsed Ph + ALL

Mesh：

Substances：

Year:  2019        PMID： 31510844     DOI： 10.1080/08880018.2019.1656685

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN： 0888-0018            Impact factor:   1.969


× No keyword cloud information.
  1 in total

1.  Efficacy of ponatinib prior to and after allogeneic hematopoietic stem cell transplantation in an adolescent with chronic myeloid leukemia in blast phase.

Authors:  Jae Wook Lee; Jae Won Yoo; Seongkoo Kim; Pil-Sang Jang; Nack-Gyun Chung; Bin Cho
Journal:  Blood Res       Date:  2021-12-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.